Latest Breaking News On - Arthritis clinical immunology research program - Page 1 : comparemela.com

AbbVie - Phase 2 Study of Upadacitinib Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active. | June 1, 2023

United statesRoopal thakkarKristin pawliwJoan merrillExchange commissionLupus erythematosus national assessmentArthritis clinical immunology research programEuropean congressOklahoma medical research foundationFlare indexLupus low disease activity stateMedical research foundationClinical immunology researchAllergan aestheticsPrivate securities litigation reform actRisk factors

Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary.

United statesJoan merrillRoopal thakkarUpadacitinib monotherapyArthritis clinical immunology research programCenters for diseaseEuropean congressLupus erythematosus national assessmentExchange commissionOklahoma medical research foundationAbbvie deutschland gmbh coBritish isles lupus assessment groupResponder indexLupus low disease activity stateFlare indexClinical immunology research

Upadacitinib Demonstrates Significant Improvements in Disease Activity, Flare in SLE

Patients treated with upadacitinib maintained greater improvements in SLE disease activity, lupus flares, and time to first flare when compared with the placebo cohort.

United statesRoopal thakkarJoan merrillEuropean congressArthritis clinical immunology research programLupus foundation of america joan merrillBritish isles lupus assessment groupOklahoma medical research foundationLupus foundationClinical immunology researchFlare indexLupus low disease activity state

Anifrolumab showed benefit across different measures of skin and joint disease activity

A new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR.

United statesJoan merrillOklahoma medical research foundationEuropean congressBritish isles lupus assessment groupArthritis clinical immunology research programActivity indexCutaneous lupus erythematosus disease areaSeverity indexClinical immunology research programExecutive vice presidentUncontrolled lupusInterferon pathwayBased composite lupus assessmentRespiratory tract infectionAutoimmune disease

AstraZeneca plc (via Public) / Anifrolumab showed benefit across different measures of skin and joint disease activity in patients with systemic lupus erythematosus

AstraZeneca plc (via Public) / Anifrolumab showed benefit across different measures of skin and joint disease activity in patients with systemic lupus erythematosus
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

United statesJoan merrillOklahoma medical research foundationEuropean congressBritish isles lupus assessment groupArthritis clinical immunology research programActivity indexCutaneous lupus erythematosus disease areaSeverity indexClinical immunology research programExecutive vice presidentUncontrolled lupusInterferon pathwayBased composite lupus assessmentAstrazeneca plc via public anifrolumab showed benefit across different measures of skin and joint disease activity in patients with systemic lupus erythematosusஒன்றுபட்டது மாநிலங்களில்